Mario L de Lemos

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi Clinical efficacy of generic imatinib
    Mario L de Lemos
    BC Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 21:76-9. 2015
  2. ncbi Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration
    Mario L de Lemos
    Provincial Systemic Therapy Program, BC Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 15:45-52. 2009
  3. ncbi Interaction between mercaptopurine and milk
    Mário L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
    J Oncol Pharm Pract 13:237-40. 2007
  4. ncbi Stability issues of parenteral chemotherapy drugs
    Mario L de Lemos
    Provincial Drug Information Coordinator, Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 13:27-31. 2007
  5. ncbi Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 12:193-9. 2006
  6. ncbi Acute reactions to chemotherapy agents
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, B C, Canada
    J Oncol Pharm Pract 12:127-9. 2006
  7. ncbi Defining the clinical improvement in cancer drug therapy: implications for priority setting in healthcare
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, B C, Canada
    J Oncol Pharm Pract 12:91-4. 2006
  8. ncbi Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies
    Mario L de Lemos
    Provincial Drug Information Coordinator, Provincial Systemic Therapy Program, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
    Gynecol Oncol 103:1063-9. 2006
  9. ncbi Management of extravasation of oxaliplatin
    Mario L de Lemos
    British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
    J Oncol Pharm Pract 11:159-62. 2005
  10. ncbi Herbal supplement PC-Spes for prostate cancer
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver V5Z 4E6, British Columbia, Canada
    Ann Pharmacother 36:921-6. 2002

Collaborators

  • Brian Thiessen
  • Nevin Murray
  • I A Olivotto
  • Sarah Jennings
  • Suzanne C Malfair Taylor
  • T Vu
  • Adeera Levin
  • C H Speers
  • Leela John
  • Saira Mithani
  • Dennis Jang
  • Robin K O'Brien
  • S C M Taylor
  • Juliana Man
  • K Kuik
  • Thanh Vu
  • Dawn Annable
  • F Hu
  • S Ellard

Detail Information

Publications18

  1. ncbi Clinical efficacy of generic imatinib
    Mario L de Lemos
    BC Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 21:76-9. 2015
    ..Generic imatinib has recently been approved for chronic myeloid leukemia in Canada and the European Union (EU). There are anecdotal concerns of reduced efficacy related to generic vs. brand name imatinib...
  2. ncbi Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration
    Mario L de Lemos
    Provincial Systemic Therapy Program, BC Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 15:45-52. 2009
    ....
  3. ncbi Interaction between mercaptopurine and milk
    Mário L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
    J Oncol Pharm Pract 13:237-40. 2007
    ..This interaction may be clinically significant. Therefore most patients should try to separate the timing of taking mercaptopurine and drinking milk...
  4. ncbi Stability issues of parenteral chemotherapy drugs
    Mario L de Lemos
    Provincial Drug Information Coordinator, Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 13:27-31. 2007
    ..Potential approaches to address these common issues are described in this article...
  5. ncbi Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 12:193-9. 2006
    ..The American Society of Clinical Oncology recommends infusion of pamidronate over 2 hours to avoid renal deterioration, although there are data to suggest that 1-hour infusions may be safe...
  6. ncbi Acute reactions to chemotherapy agents
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, B C, Canada
    J Oncol Pharm Pract 12:127-9. 2006
    ..The British Columbia Cancer Agency recently updated the list of selected drugs associated with hypersensitivity reactions and the minimum time that immediate physician coverage is needed...
  7. ncbi Defining the clinical improvement in cancer drug therapy: implications for priority setting in healthcare
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, B C, Canada
    J Oncol Pharm Pract 12:91-4. 2006
    ....
  8. ncbi Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies
    Mario L de Lemos
    Provincial Drug Information Coordinator, Provincial Systemic Therapy Program, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada
    Gynecol Oncol 103:1063-9. 2006
    ..The MDRD formula has been shown to be more accurate in non-cancer patients with chronic renal disease. We compared the accuracy of these formulae for dosing carboplatin in patients with gynecological cancers...
  9. ncbi Management of extravasation of oxaliplatin
    Mario L de Lemos
    British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
    J Oncol Pharm Pract 11:159-62. 2005
    ..Warm compress may increase drug removal by local vasodilation and avoid peripheral neuropathy. However, it may potentially increase cellular uptake and hence injury. Further research into this area is needed...
  10. ncbi Herbal supplement PC-Spes for prostate cancer
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver V5Z 4E6, British Columbia, Canada
    Ann Pharmacother 36:921-6. 2002
    ..To determine the efficacy and toxicity of the herbal supplement PC-Spes in prostate cancer patients...
  11. ncbi Advising cancer patients on natural health products--a structured approach
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Ann Pharmacother 38:1406-11. 2004
    ..Many patients with cancer (45-60%) use natural health products (NHPs). Pharmacists often find it difficult to advise these patients effectively...
  12. ncbi Pharmacist's role in meeting the psychosocial needs of cancer patients using complementary therapy
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    Psychooncology 14:204-10. 2005
    ..Given the propensity of distress in cancer patients, in general, this may provide potential benefits for patients seeking conventional and complementary therapies...
  13. ncbi Vinorelbine and venous irritation: optimal parenteral administration
    Mario L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, BC V5Z 4E6, Canada
    J Oncol Pharm Pract 11:79-81. 2005
    ..Intravenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min...
  14. ncbi Leaching of diethylhexyl phthalate from polyvinyl chloride materials into etoposide intravenous solutions
    Mario L de Lemos
    British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
    J Oncol Pharm Pract 11:155-7. 2005
    ..Recent evidence suggests that this may be more substantial than previously found. Since DEHP is potentially hepatotoxic and carcinogenic, it is preferable to prepare and administer etoposide bags and tubings made from non-PVC materials...
  15. ncbi Effects of soy phytoestrogens genistein and daidzein on breast cancer growth
    M L de Lemos
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, Canada
    Ann Pharmacother 35:1118-21. 2001
    ..To determine whether genistein and daidzein, the major phytoestrogens in soy, can stimulate breast cancer growth...
  16. ncbi Impact on patient satisfaction with a structured counselling approach on natural health products
    Suzanne C Malfair Taylor
    Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, Canada
    J Oncol Pharm Pract 14:37-43. 2008
    ..The provision of better information on NHP may improve the patient satisfaction and quality of life. We report the impact on patient satisfaction by routine counselling on NHP...
  17. ncbi Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin
    Sarah Jennings
    Provincial Systemic Therapy Program, BC Cancer Agency, Vancouver, BC, Canada
    J Oncol Pharm Pract 16:113-9. 2010
    ..Since this setting does not include routine measurement of GFR, we report the concordance of estimates of GFR derived from the CG and MDRD formulas...
  18. ncbi Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation
    T Vu
    Provincial Systemic Therapy Program, BC Cancer Agency, Vancouver, British Columbia, Canada
    Ann Oncol 19:461-4. 2008
    ..A randomized controlled trial showed longer overall survival (OS) with docetaxel compared with paclitaxel in metastatic breast cancer patients with prior exposure to anthracycline. We report a similar comparison using population-based data...